Similar articles

• Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.

  Cao DY, Yang JY, Yue SQ, Tao KS, Song ZS, Wang DS, Yang YL, Dou KF. Cao DY, et al. Cell Immunol. 2009;259(1):13-20. doi: 10.1016/j.cellimm.2009.05.007. Epub 2009 May 27. Cell Immunol. 2009. PMID: 19545862
• Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.

  Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M, Kaneko S. Mizukoshi E, et al. Hepatology. 2006 Jun;43(6):1284-94. doi: 10.1002/hep.21203. Hepatology. 2006. PMID: 16729333
• Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.

  Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H. Tang L, et al. Gene Ther. 2007 Aug;14(16):1226-34. doi: 10.1038/sj.gt.3302959. Epub 2007 Jun 28. Gene Ther. 2007. PMID: 17597794
• [Immunotherapy for hepatocellular carcinoma using dendritic cells].

  Homma S, Toda G, Ohno T. Homma S, et al. Nihon Rinsho. 2001 Oct;59 Suppl 6:693-8. Nihon Rinsho. 2001. PMID: 11762039 Review. Japanese. No abstract available.
• Potential of immunotherapy for hepatocellular carcinoma.

  Breous E, Thimme R. Breous E, et al. J Hepatol. 2011 Apr;54(4):830-4. doi: 10.1016/j.jhep.2010.10.013. Epub 2010 Nov 9. J Hepatol. 2011. PMID: 21145836 Review.